Clinical trials in pulmonary arterial hypertension: what do they tell us

R. Naeije (Beersel, Belgium)

Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Number: 19
Disease area: Pulmonary vascular diseases

PDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Naeije (Beersel, Belgium). Clinical trials in pulmonary arterial hypertension: what do they tell us. ERS Skills course - Pulmonary hypertension and pulmonary vascular disease

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different?
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016

Do we need controlled clinical trials in pulmonary arterial hypertension?
Source: Eur Respir J 2001; 17: 1-3
Year: 2001


End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
Source: Eur Respir J 2009; 34: 231-242
Year: 2009



Interpreting risk reduction in clinical trials for pulmonary arterial hypertension
Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018
Year: 2018



Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed
Source: Eur Respir J 2010; 36: 986-990
Year: 2010


Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer?
Source: Eur Respir J 2009; 33: 1247-1249
Year: 2009


Pulmonary hypertension: what can we learn from studies?
Source: International Congress 2015 – Practising personalised medicine: why, when, and how?
Year: 2015



Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready?
Source: Eur Respir J 2014; 44: 1404-1407
Year: 2014


The effects of beta-blocker therapy on systolic and diastolic function in pulmonary arterial hypertension: A randomized controlled trial
Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Year: 2014


REVEAL: a contemporary US pulmonary arterial hypertension registry
Source: Eur Respir Rev 2012; 21: 8-18
Year: 2012


Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015


Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015



“Rehab for all!” Is it too early in pulmonary arterial hypertension?
Source: Eur Respir J, 54 (5) 1901558; 10.1183/13993003.01558-2019
Year: 2019



Clinical trial design and new therapies for pulmonary arterial hypertension
Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018
Year: 2019



Image-based recommendations for the evaluation of pulmonary embolism and arterial hypertension: what? when? how?
Source: Virtual Congress 2020 – Image-based guidelines and recommendations in respiratory diseases
Year: 2020


Pulmonary arterial hypertension: treatment options
Source: International Congress 2018 – ME10 Pulmonary arterial hypertension: treatment options FULLY BOOKED
Year: 2018


Combination therapy for pulmonary arterial hypertension: still more questions than answers
Source: Eur Respir J 2004; 24: 339-340
Year: 2004


Hemodynamic and clinical relevance of “borderline pulmonary hypertension“
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
Source: Eur Respir Rev 2017; 26: 160055
Year: 2017



Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations
Source: Eur Respir Rev, 28 (154) 190050; 10.1183/16000617.0050-2019
Year: 2019